175 related articles for article (PubMed ID: 30488489)
1. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
[TBL] [Abstract][Full Text] [Related]
2. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
3. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
Minami Y; Kohsaka S; Tsuda M; Yachi K; Hatori N; Tanino M; Kimura T; Nishihara H; Minami A; Iwasaki N; Tanaka S
Cancer Sci; 2014 Sep; 105(9):1152-9. PubMed ID: 24989082
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro.
Peng C; Guo W; Yang Y; Zhao H
Eur J Cancer Prev; 2008 Oct; 17(5):392-8. PubMed ID: 18714179
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Ma H; Seebacher NA; Hornicek FJ; Duan Z
EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
[TBL] [Abstract][Full Text] [Related]
10. SS18-SSX drives CREB activation in synovial sarcoma.
Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
[TBL] [Abstract][Full Text] [Related]
11. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
12. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.
Li X; Dean DC; Yuan J; Temple TH; Trent JC; Rosenberg AE; Yu S; Hornicek FJ; Duan Z
Biomed Pharmacother; 2022 May; 149():112888. PubMed ID: 35367753
[TBL] [Abstract][Full Text] [Related]
14. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
Elife; 2018 Nov; 7():. PubMed ID: 30431433
[TBL] [Abstract][Full Text] [Related]
15. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.
Allander SV; Illei PB; Chen Y; Antonescu CR; Bittner M; Ladanyi M; Meltzer PS
Am J Pathol; 2002 Nov; 161(5):1587-95. PubMed ID: 12414507
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study.
Ito J; Asano N; Kawai A; Yoshida A
Hum Pathol; 2016 Jan; 47(1):32-7. PubMed ID: 26520417
[TBL] [Abstract][Full Text] [Related]
20. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
